Open Label Pharmacokinetic-Pharmacogenetic Study on Polymorphisms in the Organic Cation Transporter OCT1

NCT02054299 ↗

Phase 1 Completed 48 enrolled University Medical Center Goettingen

NaSingle-groupOpen-labelBasic science

Summary

The purpose of this study is to determine the effect of the organic cation transporter OCT1 polymorphisms on the pharmacokinetics of several drugs in order to explain efficacy and adverse effects.

Timeline

Start: 2013-04
Primary completion: 2016-02
Completion: 2016-02

Publications

Tzvetkov MV, Matthaei J, Pojar S, Faltraco F, Vogler S, Prukop T, Seitz T, Brockmoller J. Increased Systemic Exposure and Stronger Cardiovascular and Metabolic Adverse Reactions to Fenoterol in Individuals with Heritable OCT1 Deficiency. Clin Pharmacol Ther. 2018 May;103(5):868-878. doi: 10.1002/cpt.812. Epub 2017 Dec 8.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Amitriptyline	Small molecule	25 mg	Oral
Subject	Desvenlafaxine	Other / unclassified	50 mg	Oral
Subject	Fenoterol	Unknown	180 ug	Intravenous
Subject	Proguanil	Small molecule	200 mg	Oral
Subject	Sumatriptan	Unknown	50 mg	Oral
Subject	Thiamine	Other / unclassified	200 mg	Oral

Indications

No indication recorded.